ANI Pharmaceuticals (ANIP) AI Stock Analysis

• Market Cap: $1.36B
• Dividend Yield: N/A
• Average Volume (3M): 406.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 30.26%
• EPS Growth: -173.36%
• Country: US
• Employees: 897
• Sector: Healthcare
• Sector Strength: 55
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.70
• Shares Outstanding: 21,651,072
• 10 Day Avg. Volume: 330,362
• 30 Day Avg. Volume: 406,568
• PEG Ratio: -0.17
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -28.57
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 0.37
• Enterprise Value/Gross Profit: 2.32
• Enterprise Value/Ebitda: 2.95
• 1Y Price Target: $85.00
• Price Target Upside: 36.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 64 Neutral
• Price Target: $66.00 ▲(6.25%Upside)

ANI Pharmaceuticals' overall stock score reflects strong revenue growth and cash flow generation, which are offset by challenges in profitability and technical indicators. Increased future guidance and strategic corporate decisions provide a positive outlook, but risks from market access issues and acquisitions remain significant.

Positive Factors

Financial Performance

ANIP reported earnings highlighted by a consensus beat on revenue and adj. EBITDA and an incremental raise to 2025 guidance.

Product Launch

The beat was driven primarily by the generics segment, which benefited from a new product launch.

Regulatory Approval

The FDA approved an expanded Iluvien label, adding chronic non-infection uveitis affecting the posterior segment (NIU-PS) to the current DME indication, which came earlier than expected and reflects continued ANI regulatory execution.

Negative Factors

Legal Dispute

ANIP is currently in a legal dispute regarding the rights to receive a 5% royalty from CGON's cretostimogene sales.

Rare Disease Segment

Rare disease segment is experiencing a sequential step-down due to seasonality, which seems appropriately reflected in consensus estimates.

Risk of Generic Launch

Risks include the possibility of generic launches falling short, limited track record for Iluvien/Yutiq, and potential failure to drive Cortrophin volumes.

ANI Pharmaceuticals Business Overview & Revenue Model

Company Description

ANI Pharmaceuticals, Inc. (ANIP) is a specialty pharmaceutical company engaged in developing, manufacturing, and marketing high-quality generic and branded prescription pharmaceuticals. ANI's portfolio includes complex formulations, controlled substances, and niche generic products, serving various therapeutic areas such as oncology, hormones, and controlled substances. The company emphasizes innovation and quality to fulfill unmet medical needs while maintaining a strong commitment to regulatory compliance and quality assurance.

How the Company Makes Money

ANI Pharmaceuticals generates revenue primarily through the sale of its generic and branded pharmaceutical products. The company focuses on launching new products and expanding its portfolio to enhance its market presence. ANI leverages its manufacturing facilities to produce complex formulations and controlled substances, which often have higher barriers to entry, allowing for premium pricing and reduced competition. The company also forms strategic partnerships and collaborations to expand its reach and capabilities. Significant factors contributing to ANI's earnings include its ability to bring new products to market efficiently, manage its supply chain effectively, and maintain strong relationships with key stakeholders such as healthcare providers, distributors, and regulatory bodies.

ANI Pharmaceuticals Financial Statement Overview

Summary

ANI Pharmaceuticals exhibits strong revenue growth and cash flow generation. However, it faces challenges with net profitability and ROE due to ongoing expenses and financial costs. The balance sheet shows moderate leverage but needs improvement in equity returns.

Income Statement

ANI Pharmaceuticals has shown a consistent increase in revenue over the years, with a notable TTM growth rate of approximately 9.71% from the previous year. The gross profit margin for the TTM is 57.14%, indicating strong product profitability. However, the net profit margin remains negative at -3.12% for the TTM, highlighting ongoing challenges in controlling expenses or non-operational costs. The EBIT and EBITDA margins are positive but modest, suggesting room for operational efficiency improvements.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.76, reflecting a balanced approach to leverage. However, the return on equity is negative at -5.03% for the TTM due to net losses, indicating inefficiencies in generating returns for shareholders. The equity ratio is 32.39%, suggesting a reasonable level of equity financing, but there is room for strengthening the equity base to improve financial stability.

Cash Flow

ANI Pharmaceuticals' cash flow statement reveals a strong free cash flow growth of 45.28% in the TTM, demonstrating effective cash generation capabilities. The operating cash flow to net income ratio is favorable at 3.84, indicating good cash earnings conversion. The free cash flow to net income ratio is also positive at 3.25, highlighting efficient cash management despite net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
674.07M	614.38M	486.82M	316.38M	216.14M	208.47M
	Gross Profit
385.28M	364.17M	305.30M	177.60M	115.53M	121.32M
	EBIT
6.83M	584.00K	46.97M	-25.06M	-32.51M	-16.06M
	EBITDA
76.14M	79.15M	106.60M	48.07M	-1.68M	29.07M
	Net Income Common Stockholders
-21.05M	-18.52M	18.78M	-47.90M	-42.60M	-22.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.80M	151.17M	221.12M	48.23M	100.30M	7.86M
	Total Assets
1.29B	1.28B	904.42M	760.09M	771.60M	461.19M
	Total Debt
317.53M	624.09M	285.67M	286.52M	287.37M	185.69M
	Net Debt
167.73M	479.23M	64.55M	238.29M	187.07M	177.82M
	Total Liabilities
848.96M	855.17M	446.82M	421.55M	412.86M	265.49M
	Stockholders Equity
418.62M	428.53M	457.60M	338.54M	358.74M	195.70M
Cash Flow		Free Cash Flow
68.37M	47.06M	100.45M	-47.66M	-20.32M	-53.05M
	Operating Cash Flow
80.74M	64.02M	118.96M	-31.20M	3.32M	15.27M
	Investing Cash Flow
-433.50M	-404.72M	-18.51M	-15.74M	-105.48M	-68.32M
	Financing Cash Flow
274.76M	264.94M	67.44M	-5.13M	194.59M	-1.44M

ANI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 62.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Positive. The current price of 62.12 is above the 20-day moving average (MA) of 60.15, below the 50-day MA of 65.17, and above the 200-day MA of 60.37, indicating a neutral trend. The MACD of -0.71 indicates Negative momentum. The RSI at 51.80 is Neutral, neither overbought nor oversold. The STOCH value of 84.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANIP.

ANI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	79 Outperform	$1.27B	9.45	19.90%	―	8.05%	-8.46%
COLL	76 Outperform	$976.16M	24.47	19.23%	―	17.17%	-51.97%
SUPN	73 Outperform	$1.86B	30.02	6.32%	―	11.82%	―
ANIP	64 Neutral	$1.36B	―	-5.19%	―	30.26%	-173.36%
PCRX	59 Neutral	$1.15B	―	-12.27%	―	3.08%	-247.82%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
DVAX	48 Neutral	$1.25B	64.45	-10.45%	―	24.76%	-783.38%

ANI Pharmaceuticals Corporate Events

ANI Pharmaceuticals Highlights Financial Performance Amid Challenges

ANI Pharmaceuticals has highlighted its financial performance indicators, emphasizing the importance of adjusted non-GAAP EBITDA and diluted earnings per share as measures of its operating performance. The company is addressing the impact of recent acquisitions, supply chain disruptions, and regulatory challenges on its operations, while also focusing on maintaining profitability and market acceptance of its products.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Approves Key Proposals at Annual Meeting

ANI Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 22, 2025, where several key proposals were approved. These included amendments to the company’s stock plans and an increase in authorized shares of common stock, reflecting strategic moves to bolster its financial and operational flexibility. The meeting also saw the election of eight directors and the ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm, indicating a stable governance and financial oversight structure for the upcoming fiscal year.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Releases May 2025 Financial Presentation

ANI Pharmaceuticals has released a corporate presentation detailing its financial performance and strategic initiatives as of May 2025. The company emphasizes the importance of adjusted non-GAAP financial measures, such as EBITDA and diluted earnings per share, as key indicators of its operating performance. These metrics exclude various non-cash and one-time expenses to provide a clearer picture of the company’s financial health. The presentation also highlights potential risks and uncertainties, including supply chain disruptions and regulatory challenges, which could impact its operations and financial results.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Files Proxy for 2025 Meeting

On April 10, 2025, ANI Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting of shareholders to consider several proposals, including the approval of the Amended and Restated 2022 Stock Incentive Plan. The company issued a Proxy Supplement to clarify that non-shareholder approved inducement grants are included in the share reserve increase proposal. As of March 24, 2025, ANI Pharmaceuticals had 1,177,800 shares available for future grants under the Stock Plan, which is deemed insufficient to attract and retain key talent. The company emphasizes the importance of the Stock Plan in its compensation strategy, aligning with market standards to motivate and retain employees.